By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


GlycoVaxyn AG 

Ditch Route 3

Streaks    8952  Switzerland
Phone: 41-44-733-85-85 Fax: 41-44-733-85-74




Company News
GlaxoSmithKline (GSK) Takes Full Control of GlycoVaxyn AG for $190 Million 2/11/2015 5:51:46 AM
GlycoVaxyn AG Announces The Initiation Of A Phase I Clinical Trial In Collaboration With Janssen Pharmaceutical Inc. For A Vaccine Against Extra-Intestinal Pathogenic Escherichia Coli Causing Urinary Tract Infection 7/1/2014 9:58:53 AM
GlycoVaxyn AG Secures CHF 5.1 Million Strategic Translation Award From the Wellcome Trust to Finance Clinical Development of Shigella Vaccine 7/29/2013 9:17:48 AM
GlycoVaxyn AG Announces Addition of Gerd Zettlmeissl, as Chairman of the Board of Directors 3/6/2013 6:50:02 AM
GlycoVaxyn AG Signs Exclusive License Agreement and Enters Research and Development Collaboration With Janssen Pharmaceuticals, Inc., to Develop Multi-Valent Bacterial Vaccine 1/4/2013 9:58:53 AM
GlycoVaxyn AG Announces Strategic Collaboration With GlaxoSmithKline (GSK) to Develop New Bacterial Vaccines using GlycoVaxyn's Bio-Conjugation Technology 12/19/2012 9:05:22 AM
GlycoVaxyn AG's Staphylococcus aureus Bioconjugate Vaccine Candidate Protects Mice Against Invasive S. aureus Infection 9/16/2011 10:37:06 AM
GlycoVaxyn AG to Host Second Annual Science Day to Discuss Challenges and Opportunities in Vaccine Development 6/15/2011 7:03:59 AM
GlycoVaxyn AG Phase I Clinical Study Shows Positive Data with Shigella Dysenteriae Vaccine Candidate 10/8/2010 9:39:22 AM
GlycoVaxyn AG and a Harvard University Affiliated Hospital Receive USD 3.4 Million National Institutes of Health (NIH) Grant for Staphylococcus aureus Vaccine Development 5/4/2010 6:59:45 AM